Why the study?
There are no FDA-approved therapies to safely enhance cardiomyocyte protein quality control, predominantly due to a lack of knowledge regarding proteins regulating it.
Stimulating protein kinase G represents a promising therapeutic strategy to enhance protein quality control and treat cardiac proteotoxicity in heart failure.
Answers are grounded in this paper and cite their sources.
Targeting PKG/PQC may improve HF outcomes; leaves open clinical translation from pre-clinical models.
Impaired or insufficient protein kinase G (PKG) signaling and protein quality control (PQC) are hallmarks of most forms of cardiac disease, including heart failure. Their dysregulation has been shown to contribute to and exacerbate cardiac hypertrophy and remodeling, reduced cell survival and disease pathogenesis. Enhancement of PKG signaling and PQC are associated with improved cardiac function and survival in many pre-clinical models of heart disease. While many clinically used pharmacological approaches exist to stimulate PKG, there are no FDA-approved therapies to safely enhance cardiomyocyte PQC. The latter is predominantly due to our lack of knowledge and identification of proteins regulating cardiomyocyte PQC. Recently, multiple studies have demonstrated that PKG regulates PQC in the heart, both during physiological and pathological states. These studies tested already FDA-approved pharmacological therapies to activate PKG, which enhanced cardiomyocyte PQC and alleviated cardiac disease. This review examines the roles of PKG and PQC during disease pathogenesis and summarizes the experimental and clinical data supporting the utility of stimulating PKG to target cardiac proteotoxicity.
No takes yet. Share an insight, caveat, or question.
Oeing et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: